SITEMAP
-
Science
- Cutting Edge Science
- Inspiration and Innovation
- Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
- Allergic Rhinitis
- Anti-Infectives
-
Asthma
-
Cutting Edge Science
- 2021
-
Innovation
- Dupixent reduce Asthma Exacerbation across different type of patients
- Prevalence of Asthma
- What beneficial impact does Dupixent have on OCS-Dependent patients?
- What is your experience with Dupixent in your practice?
- Managing Severe Asthma and CRSwNP through the lens of type 2 inflammation
- What feedback have you received from patients being treated with Dupixent?
- Why is it important to measure FEV1 in patients with asthma?
- How does Dupixent help reduce asthma exacerbations across multiple phenotype
- Asthma Assessment Tools (EPOS)
- How does Dupixent target the underlaying type2 inflammation in asthma?
- What gives you confidence that Dupixent improves patients’ quality of life?
- Why is it important to look for Type 2 inflammation in patients with Asthma?
- How do you balance the cost of Biologics with the value they can bring to patients?
- How Type 2 inflammation affect patients with Asthma?
- What challenges do you face when treating patients with Type 2 inflammation?
- When do you discuss Biologic treatment with your Asthma patients?
- How do you choose the right Biologic for a particular Asthma patients?
- Asthma Control Tests (ACT) overview
-
2022
- How to inject Dupixent
- What's possible when their Child's Asthma is under control?
- Discover a solution to control mixed Eosinophilic and Allergic Asthma
- Dupixent® (dupilumab) Mechanism of Action
- Consider Dupixent for Asthmatic patients with OCS use
- Consider Dupixent for Asthmatic patients with high EOS
- 2023
-
2024
-
Cutting Edge Science
- Atopic Dermatitis
-
Cardiovascular
-
Atherothrombosis
-
Cutting Edge Science
- Innovation
-
2022
- Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice
- In hospital outcomes in young patients with AMI: Results from Gulf Coast
- Adherence and persistence analysis in patients treated with DAPT
- Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)
- Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?
-
2023
- De-escalation to Clopidogrel in AMI
- Ticagrelor vs Clopidogrel in high bleeding risk patients with ACS
- DAPT for secondary prevention of AIS
- Clopidogrel Based Strategies in ACS
- Ticagrelor vs Clopidogrel in high bleeding risk patients with ACS
- Unguided de-escalation from Ticagrelor to Clopidogrel
- P2Y12 inhibitor adherence trajectories in ACS
-
Cutting Edge Science
-
Dyslipidemia
-
Cutting Edge Science
-
2021
- Heart UK Reviews Safety of Lipid Lowering Medications in Patients with COVID-19
- The ROSETTE Study
- Regulate LDL-C level for those undergoing coronary revascularization (Diabetic Patients)
- Real-life safety and efficacy of Alirocumab - Odyssey apprise study
- Optimal use of LLT after ACS
- Italian real-world analysis for PCSK9 inhibitors new users
- NEJM Odyssey outcomes
- Odyssey outcomes
- Odyssey outcomes - elderly patients results
- Odyssey outcomes - CABG results
- Odyssey outcomes - PVD results
- Odyssey outcomes - total events results
- Odyssey outcomes - mortality
- ESC/EAS 2019 international guidelines
- Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress
- Odyssey Outcomes - PVD Sub-analysis
- Odyssey Outcomes - Total Events Analysis
- Odyssey outcomes - CVOT mortality sub-analysis
- Effect of Alirocumab on MACE in patients with CKD
-
Innovation
- Managing the Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2
- Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients
- Lp(a) as ASCVD risk factor
- Atherosclerosis: Identifying risks and improving outcomes
- Managing the Recurrent ASCVD risk of your ACS Patient: A call to Action – Gulf Perspective: Part 3
- Managing the Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 1
- Metabolic Risk Factors and Effect of Alirocumab on CV Events
- Act Now for Your ACS Patients: Optimise Your ACS Pathway
- Act Now for Your ACS Patients: Summary
- Overview of adherence data with LLT highlighting the most recent data with PCSK9i
- Treating to target in clinical practice: Why is it important to achieve recommended LDL-C levels?
- Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early
- Improving Lipid Management for Patients Post-ACS
- Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines
- The role of the patient in Achieving LDL-C Target
- EAS guidance regarding combining Lipid-modifying therapy
- Lipid management in patients with ACS/ASCVD
- 2022
-
2022
- Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia
- Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines
- Evaluation of lipid management following ACS
- The European experience: Swedeheart and AIFA registries
- Perceptions and Barriers on the use of PCSK9 inhibitors
- Clinical practice experience in patients with familial hypercholesterolemia (FH) from the Safeheart registry
- PCSK9 inhibitors and ACS
- Prognostic impact of achieving LDL cholesterol guidelines
- Statin/Ezetimibe Combination VS Statin Monotherapy
- Should we encourage earlier and broader use of combination therapies in dyslipidemia?
- Possible Challenges Post One Year of ESC/EAS Guidelines
- PCSK9i after hospital discharge for acute MI
- PCSK9 Inhibitors in Real World Practice
- PCSK9i and Prevention of CVD
- Achievement of ESC/EAS LDL-C Treatment Goals After an ACS with Statin and Alirocumab
- LDL-C The Only Causal Risk Factor for ASCVD
- APSC Consensus Recommendations on Dyslipidemia
- CV Risk management in T1DM using guidelines
- Atherosclerotic Cardiovascular Disease Risk Assessment
- ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci
- Event rates and Risk Factors for Recurrent CV Events
- Role of Genetic Testing in Management of Dyslipidemia
- PCSK9 Inhibitors in Cardiovascular Disease
- LLTs and Antithrombotic Therapy in PAD
- LDL-C Targets in Patients with Heterozygous Familial Hypercholesterolemia
- Public health recommendations for Lp(a) measurement
- Relationship Between LDL-C LLTs and Risk of Stroke
- ESC Lp(a) in Clinical practice EAS Consensus statement
- Why compromise for less: Should PCSK9 inhibitors be initial therapy?
- LLTs Exposure Time and Major Vascular Risk Reduction
- 2023
-
2021
-
Cutting Edge Science
- Hypertension
-
Thrombosis
-
Cutting Edge Science
-
2021
- VTE prophylaxis in medically ill patients
- Impact of anemia on long-term clinical outcomes in venous thromboembolism: Findings from Garfield-VTE registry
- Safety profile of preoperative administration of low-molecular-weight heparin for Lung Cancer population
- Risk factors of lower extremity DVT in patients undergone gynecological laparoscopic surgery
- Duration of thromboprophylaxis following major abdominopelvic cancer-related surgery
- Enoxaparin monotherapy vs UFH monotherapy among inpatients with NSTEMI
- Incident heart failure tied to increased long-term risk for VTE
- VTE incidence after cesarean delivery
- Unmet clinical needs in the management of VTE in at-risk patients
- Risk for VTE is higher in emergency surgery than elective procedures
- Gaps trial: Low-dose LMWH and GCS in in elective surgical inpatients at moderate or high risk VTE
- ASH 2019 Guidelines for Surgical Prophylaxis
- VTE Prophylaxis in Surgical Patients
- Acute Medical Illness: Advanced Age Alone Predicts Venous Thromboembolism Similar to Existing Risk Assessment Models
-
2022
- Risk for thromboembolic and bleeding events in patients with haematological cancers
- Changing trends in VTE: Pulmonary Embolism cases on Rise within the Last Decade
- Global use of RAM and Thromboprophylaxis in hospitalized patients
- Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
- Benefit of Prophylaxis for High-Risk Surgical Patients
- Thematic review on Perioperative Venous Thromboembolism Prophylaxis
- Independent Risk Factors for Venous Thromboembolism
- Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent Venous Thromboembolism (VTE)
- Prolonged Thromboprophylaxis with LMWH after Abdominal or Pelvic Surgery
- Risk for Post-operative Venous Thromboembolism in Patients Receiving Enoxaparin Prophylaxis
- Trends in Pulmonary Embolism-related mortality in Europe
- 2019 ESC Guidelines for Acute Pulmonary Embolism
- Risk for Pulmonary Embolism Continues Beyond 6 Weeks of Surgery
- VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients
- Utility of Pregnancy - Adapted Years Algorithm in Diagnosis of Pulmonary Embolism
- Maternity Clot Risk Model to Predict Women at Risk of VTE
- Major GI Bleeding in VTE RIETE Analysis
- Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery
- Innovation
- 2023
-
2021
-
Cutting Edge Science
- Cutting Edge Science
-
Atherothrombosis
- Chronic Obstructive Pulmonary Disease
-
Diabetes
-
Cutting Edge Science
-
2021
- Unmet needs in adults with T2D receiving premixed insulin
- The Bright Study
- New technologies in Type 2 Diabetes management and future opportunities to improve clinical outcomes
- Insulin Treatment Intensification with GLP - 1RA vs Basal - Plus/Basal - Bolus Regimens
- Hospitalization Rates for Acute Diabetes Complications Before and After Flash Glucose Monitoring Initiation Among People with Type 1 or Type 2 Diabetes in France: The Relief Study
- A Cross-Sectional Analysis of Glycemic Control in Elderly People with Type 2 Diabetes Attending Primary Health Care Unit
- Basal Insulin and Beyond: Advanced Therapies for Type 2 Diabetes
- Prevalence of Diabetes in Children and Adolescents
- Reducing risk of severe hypoglycemia - iNPHORM Study
- The Lixilan-L Study
-
Innovation
- EVOLUTION: RWE from Saudi Arabia
- The InRange Study
- Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
- Time-In-Range (TIR): How to interpret it and how it is associated with outcomes
- SoliMix Study Results Summary
- T1DM Mini-Series: The main challenge for the kids and adolescents with T1
- Gulf sub-group analysis of the real-world Orion study
- T1DM Mini-Series: Severe hypoglycaemia compromises the achievement of glycaemic control
- Do historical HbA1c values explain glycemic legacy effect of type 2 diabetes?
- T1DM Mini-Series: Clinical implications of having hyperglycaemia with ketosis
- ATTD 2021: Technology supporting initiation, titration and intensification
- Diabetes Your Type: Testimonial by Dr. Bassam
- T1DM Mini-Series: Edition Junior trial results
- T1DM Mini-Series: Relevance of Edition JUNIOR trial results for the HCP and Patient life
- T1DM Mini-Series: How does Hypoglycaemia impact the life of people with T1 Diabetes?
- T1DM Mini-Series: How to Avoid Hypoglycaemia in People with T1 Diabetes?
- The SoliRam observational study
- Expert consensus statement on management of older adults with Type 2 Diabetes (T2D)
- Is premixed insulin an effective treatment for type 2 Diabetes uncontrolled by OADs?
- Summary of SAGE study on adults with T1DM
- ATTD 2021: Patients’ profiles for digital tools
- The value of Time-in-range
- Impact of Time-in-Range
- What is Time-in-range?
- Understanding Time-in-Range, its assessment, and targets to aim for
- Real-world evidence of treatment intensification in people with T2D inadequately controlled on GLP-1 RAs
- ADA 2021: Solimix Trial Summary
- Diabetes your type: Testimonial by Dr. Nadia
- Diabetes your type: Testimonial by Dr. Hussein
- 2022
-
2022
- Patient awareness and attainment of goals in Type 2 Diabetes Mellitus: A real-world survey
- Diabetes management during Ramadan
- Results from the SoliRam observational study
- Post-exercise hypoglycemia in relation to medication regimen among adults with type 2 diabetes
- Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
- Closed-loop insulin delivery during exercise in people with T1DM
- A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan
- Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement
- Advancing therapy in suboptimally controlled Basal insulin-treated Type 2 Diabetes (SoliMix)
- 2023
-
2024
- Unveiling Significance of Time in Range: Value as key Glycemic Biomarker
- Need to redefine the treatment paradigm Post OAD
- SoliCGM Synergy: Soliqua’s Synchronized Impact on T2DM CGM Dynamics Therapy
- The Evolving Role of Treatment and Technology in Diabetes Care
- An Evidence about The Role of Basal Insulin Glargine 300 U/mL Post-GLP-1 Therapy
- Connectivity Canvas: Pioneering Diabetes Management with Connected Insulin Caps
- Inside Diabetes: ATTD Edition | Type 1 Diabetes
-
2021
-
Cutting Edge Science
- Eosinophilic Esophagitis
- Microbiota and Probiotics
- Multiple Myeloma
-
Multiple Sclerosis
-
Cutting Edge Science
- Innovation
-
2022
- The reason for MS – beyond focal inflammation
- The importance of deep grey matter in MS
- Measuring brain atrophy. What can be done and where are we heading?
- Falling chronically ill – How do I cope and move forward?
- Cognitive decline – The invisible burden of MS?
- Cognitive training – A curse or a blessing?
- How old is your brain?
- Exercise as ”medicine” in the treatment of MS
- A promising biomarker in MS: Neurofilament light chain
- Why has our brain suddenly become of interest?
- Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice
- MS Updates
-
2023
-
Cutting Edge Science
-
Nasal Polyps
-
Cutting Edge Science
- 2021
- 2022
-
2023
- Hear From An Expert On Identify Patients Who Are Appropriate Candidates For Biologic Treatment
- Hear from an expert on what does Dupixent bring to your practice?
- Expert opinions: Would you consider a biologic for a CRSwnp patient who has had Sinus surgery?
- Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?
- Hear from an expert on what have you learned from your experience with biologics?
- Hear from an expert on would you consider a biologic for a Surgery-naïve Patient with CRS with Nasal Polyps?
- Hear From An Expert On What Does The Future Of Treatment Look Like For Crs With Nasal Polyps?
- Hear from an expert on how do you address Patients' concerns about Sinus surgery?
- Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases
- Hear from an expert on how do you manage treatment compliance issues in Patients with CRS with Nasal Polyps?
- Hear From An Expert On The Type 2 Immune Response And Inflammation
- Hear from an expert on what are the main challenges in treating Patients with CRS with Nasal Polyps?
- Type 2 Inflammation is the underlying cause of CRSwNP in 80% of Patients.
- NPS improvement with Dupixent over time
- IL4/IL13 are the central cytokines for type 2 inflammation in CRSwNP
- You can imagine more than 90% of CRSwNP patients losses their ability's of smell
- Compelling trial results: CRS with nasal polyps
- What does patient empowerment mean for your treatment plan?
- “Smell—we call it the Cinderella of the senses"
- "It really has changed the way I manage our patients"
- How do you factor safety into treating patients with CRSwNP?
- How does Dupixent help recover smell?
- What can biologic treatment do for patients with CRS with nasal polyps?
- When Dupixent is available, I would say go for it
-
Cutting Edge Science
- Neurological Disorders
-
Prurigo Nodularis
-
Cutting Edge Science
-
2022
- There is Significant Unmet Need in the Management of PN¹
- Mechanism of Prurigo Nodularis Disease
- Prurigo Nodularis is a Distinct, Chronic, Neural and Immune- Mediated skin Disease characterized by Intense Itch and Nodular Lesions¹
- Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology¹
- 2023
- 2024
-
2022
-
Cutting Edge Science
-
Rare Diseases
-
Cutting Edge Science
-
Innovation
- Pompe don’t lose time video
- Gaucher disease awareness month video
- How To Diagnose LSDs?
- Better care for Fabry
- Extraordinary measures: what are the benefits to have such movies talking about Rare Diseases?
- Diagnostic Algorithm for Gaucher Disease in Pediatric
- Diagnostic Algorithm for Gaucher Disease in Adult
- Bone Monitoring Guidelines in Gaucher Disease Video
- MPSI chase the signs video
- Have you considered Pompe Disease?
- The role and importance of Patients Associations and Scientific societies ; UAE experience
- IOPD Challenges
- Multidisciplinary approaches in Rare Disease Patient management in KSA
- What are the new diagnostics modalities used to expedite Rare Disease patients identification?
- Fabry Disease from Cardiology Perspective
- When shall we think of a rare disease from Neurological perspective
- What are Lysosomal Storage disorders?
- Lysosomal Storage Diseases from Neurology Perspective
- The Stigma of Rare Diseases
- The role and importance of Patients Associations and Scientific societies ; Oman Experience
- Multidisciplinary approaches in Rare Disease Patient management
- How is LSDs prevalence & epidemiology different in our region?
- What is the role of Artificial Intelligence in accelerating patient's diagnosis?
- LSDs overview
- Respiratory Impairment in Acid Sphingomyelinase Deficiency (ASMD): A Case Report.
- Professor Fatma Al-Jasmi video on ASMD
- Professor Tawfeq Ben Omran video on ASMD
- Professor Moeen Al Sayed video on ASMD
- Pompe video
- Diagnostic challenges of LOPD
- Early diagnosis and management of IOPD
- Inspiring Stories of Patients Living with ASMD
- Their Stories shaped them like Pearls
- The Role of Pediatrician in Gaucher Disease
- ASMD Phenotypes
- 2022
- 2022
-
2023
- Gaucher
- An overview of Lysosomal Storage Disorders & Sanofi`s Commitment to the Development and Provision of Treatments
- Experts recommendations on Late Onset Pompe Disease (LOPD) differential diagnosis from GCC
- Expert group consensus from the Arabian Peninsula on the diagnosis of Late Onset Pompe Disease (LOPD)
- Expert group consensus from the Arabian Peninsula on the diagnosis of Late Onset Pompe Disease for Orthopedists
- Differential diagnosis of Late Onset Pompe Disease (LOPD) and myotonic dystrophy type 1 through abdominal ultrasonography
- Prevalence of LOPD in patients with undifferentiated proximal myopathy and undiagnosed muscle biopsy
- Expert group consensus from the Arabian Peninsula on the diagnosis of LOPD
- Expert group consensus from the Arabian Peninsula on the diagnosis of LOPD
- MPSI
- Fabry
- Pompe
-
2024
- What Are the Signs and Symptoms of ASMD?
- Pompe Care Podcast Series
- Management of ASMD - Expert opinion: Professor Tawfeq Ben Omran
- Management of ASMD - Expert opinion: Professor Moeen Al Sayed
- Navigating the Pompe Disease Journey
- Differential Diagnostics for ASMD in Patients Suspected to have GD
- Impact of symptoms and risk of ASMD on patients and caregivers
- Consensus Guidelines for the Clinical Management of ASMD
- Role of Ecg in Differential Diagnosis of Anderson - Fabry Disease with HCM
- Diagnosing Fabry Disease in Clinical Practice
- Biochemical Diagnostic Strategy in Females Suspected of Fabry Disease
- Management of ASMD - Expert opinion: Professor Fatma Al- Jasmi
-
Innovation
-
Cutting Edge Science
-
Vaccines
-
Influenza
-
Cutting Edge Science
- Innovation
-
2022
- Dr. Wafaa Faysal raises urgency on influenza in pediatric population
- Dr. Khadija Hafidh on the urgency of influenza in diabetic patients
- Influenza-Focus on Diabetic Patients
- Flu & People with Heart Disease
- Raise Urgency on Influenza
- Take a Stand Against Influenza: Focus on COPD Patients
- Take a Stand Against Influenza: Focus on Children
-
Cutting Edge Science
- Meningitis
- Pertussis Polio
- RSV
-
Influenza
- Transplant
-
Patient Support
- Patient Support Articles
- Allergic Rhinitis
-
Asthma
- Atopic Dermatitis
- Cardiovascular
- Diabetes
- Rare Diseases
- Patient Resources
- Products
-
Events
- Cardiovascular
-
Diabetis
- 2021
-
2022
- Diatour Inquiry Form
- Innovation of Iglarlexi in Intensification
- Ultimate Need for Intensification
- The Role of Basal Insulin in Type 2 Diabetes Webinar
- Leveraging Time-In-Range to Improve Patient Experience
- Navigate new destinations in diabetes management
- Type 2 Diabetes Cost Effective Management
- Diabetes Guidelines in Ramadan
- Nutrition and Insulin management in Ramadan
-
2023
- Rare Disease
- Multiple Sclerosis
- Vaccines
- Prurigo Nodularis
- Anti Infectives
- Neurological Disorders
- Allergic Rhinitis
- Search
- Cookie Policy
- Legal Notice
- Privacy Policy
- Error 404
- Sanofi in News
- Registration